Kane Biotech Inc. (KNE.V)

0,1400 0,0000 (0,00%) Börsenschluss: 09:38AM EDT

Kane Biotech Inc.

100 Innovation Drive
Suite 290
Winnipeg, MB R3T 6G2
Canada
204-453-1301
https://kanebiotech.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Marc Edwards	President, CEO & Director	268,5k	N/A	N/A
Mr. Ray Dupuis	Chief Financial Officer	161,69k	N/A	N/A
Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC	Executive Chairman & Member of Scientific Advisory Board	N/A	N/A	1965
Dr. Gregory S. Schultz Ph.D.	Chief Scientific Officer & Member of Scientific Advisory Board	N/A	N/A	1950
Lorne Gorber	Investor Relations	N/A	N/A	N/A
Ms. Lori Christofalos	Vice President of Quality & Compliance	N/A	N/A	N/A
Ms. Wendy Nachtigall	Director of Marketing	N/A	N/A	N/A
Nicole Sendey	Investor Relations Adviser	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in CAD.

Beschreibung

Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand. The company is also developing coactiv+ Antimicrobial Surgical Hydrogel for use in surgical/acute wounds; coactiv+ Antimicrobial Wound Rinse for use in acute and chronic wounds; coactiv+ Antimicrobial Wound Gel Spray for use in acute, chronic wounds, and first and second degree burns; and DispersinB Hydrogel for prosthetic joint infection. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.

Corporate Governance

Kane Biotech Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.